ClinicalTrials.Veeva

Menu

Probiotic LR08 Improves Gut and Metabolism

W

Wecare Probiotics

Status

Completed

Conditions

Healthy Adults

Treatments

Dietary Supplement: Placebo
Dietary Supplement: Probiotic

Study type

Interventional

Funder types

Industry

Identifiers

NCT06875362
WK20250308

Details and patient eligibility

About

Evaluate the efficacy and safety of LR08 as a dietary supplement compared to a placebo in enhancing intestinal health and immune function in healthy adults.

Enrollment

48 patients

Sex

All

Ages

18 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Willing to attend 3 follow-up visits during the intervention period
  2. Agree to provide blood, urine, and stool samples twice during the intervention period
  3. Good eyesight, able to read and write, and capable of wearing glasses if needed
  4. Good hearing and able to fully comprehend all instructions during the intervention

Exclusion criteria

  1. Presence of digestive diseases, particularly gastrointestinal disorders (e.g., celiac disease, ulcerative colitis, Crohn's disease)
  2. History of serious neurological conditions (e.g., epilepsy, stroke, severe head trauma, meningitis within the last 10 years, brain surgery, brain tumor, or prolonged coma-not including general anesthesia)
  3. History of or currently receiving treatment for mental health disorders such as alcohol/drug/substance abuse, schizophrenia, psychosis, or bipolar disorder
  4. Currently taking medication for depression or low mood
  5. Presence of internal organ failure (e.g., heart, liver, or kidney failure)
  6. History of radiation therapy or chemotherapy treatments
  7. Underwent general anesthesia within the past three years or are scheduled for general anesthesia within the next 3 months during the trial period
  8. History of hepatitis (B or C), HIV, or syphilis

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

48 participants in 2 patient groups, including a placebo group

Probiotic group
Active Comparator group
Description:
Intervention with probiotic LR08 (30 billion CFU/day, 3g) was administered daily for 8 weeks.
Treatment:
Dietary Supplement: Probiotic
Placebo group
Placebo Comparator group
Description:
Every day to give 3 g maltodextrin intervention for 8 weeks.
Treatment:
Dietary Supplement: Placebo

Trial contacts and locations

1

Loading...

Central trial contact

Fei Xu, Doctor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems